(BN) Boeing Secures $4.6 Billion China Eastern Order for New Aircraft

Boeing Secures $4.6 Billion China Eastern Order for New Aircraft
2015-07-09 09:03:17.94 GMT


By Anand Krishnamoorthy
(Bloomberg) -- Boeing Co. won an order from China Eastern
Airlines Corp. valued at $4.6 billion in list prices for single-
aisle jets as Chinese carriers purchase new planes amid surging
travel demand.
China Eastern ordered 50 single-aisle 737 aircraft, the
Shanghai-based carrier said in a statement to the Hong Kong
stock exchange Tuesday. Each plane has a price of about $91
million, the company said in the statement, though airlines
usually get discounts from list prices. The planes would be
delivered between 2017 and 2019.
Last year, China Eastern placed an order for 80 737 jets
valued at $7.4 billion. Chinese carriers are bringing in more
orders for Boeing and its European rival Airbus Group SE as
growth in the world’s second-largest economy enables more people
to fly. China is poised to become the world’s biggest travel
market in under two decades.

For Related News and Information:
Boeing Expects to Hand Over 140 Planes to China This Year (1)
NSN MZS5K76KLVSH <GO>
Boeing Sees China Demand at 5,580 Planes Over Next 20 Years
NSN MSN1JQ6JTSFE <GO>
Top Stories:TOP<GO>

To contact the reporter on this story:
Anand Krishnamoorthy in Singapore at +65-6212-1165 or
anandk@bloomberg.net
To contact the editors responsible for this story:
Anand Krishnamoorthy at +65-6212-1165 or
anandk@bloomberg.net
Michael S. Arnold

>>> Regeneron Pharms and Sanofi (SNY) present results from ongoing 52 week ODYSS

Regeneron Pharms and Sanofi (SNY) present results from ongoing 52 week ODYSSEY JAPAN trial showing LDL-C reductions in more than 60% of patients

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent Injection met its primary endpoint.
  • At week 24, patients in the Praluent group experienced an average 64% greater reduction from baseline in their bad cholesterol, known as low-density lipoprotein cholesterol (LDL-C), when added to current standard of care including statins, compared to standard of care alone
  • Patients were started on the lower dose of 75 mg, with the option to adjust their dose to 150 mg if they had not achieved their LDL-C goal (as defined by the Japan Atherosclerosis Society guidelines) at week 8. At week 24, 97% of patients in the Praluent group reached their LDL-C treatment goal, compared to 10% for placebo
  • Ninety-nine% of patients treated with Praluent remained on the lower dose; two patients required adjustment to the higher dose.